Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nam, KeeSoo | - |
dc.contributor.author | Son, Seog-Ho | - |
dc.contributor.author | Oh, Sunhwa | - |
dc.contributor.author | Jeon, Donghwan | - |
dc.contributor.author | Kim, Hyungjoo | - |
dc.contributor.author | Noh, Dong-Young | - |
dc.contributor.author | Kim, Sangmin | - |
dc.contributor.author | Shin, Incheol | - |
dc.date.accessioned | 2021-08-02T15:28:06Z | - |
dc.date.available | 2021-08-02T15:28:06Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2017-05 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/20361 | - |
dc.description.abstract | Galectin-1 is a beta-galactoside binding protein secreted by many types of aggressive cancer cells. Although many studies have focused on the role of galectin-1 in cancer progression, relatively little attention has been paid to galectin-1 as an extracellular therapeutic target. To elucidate the molecular mechanisms underlying galectin-1-mediated cancer progression, we established galectin-1 knock-down cells via retroviral delivery of short hairpin RNA (shRNA) against galectin-1 in two triple-negative breast cancer (TNBC) cell lines, MDA-MB-231 and Hs578T. Ablation of galectin-1 expression decreased cell proliferation, migration, invasion, and doxorubicin resistance. We found that these effects were caused by decreased galectin-1-integrin 1 interactions and suppression of the downstream focal adhesion kinase (FAK)/cSrc pathway. We also found that silencing of galectin-1 inhibited extracellular signalregulated kinase (ERK)/signal transducer and activator of transcription 3 (STAT3) signaling, thereby down-regulating survivin expression. This finding implicates STAT3 as a transcription factor for survivin. Finally, rescue of endogenous galectin-1 knockdown and recombinant galectin-1 treatment both recovered signaling through the FAK/c-Src/ERK/STAT3/survivin pathway. Taken together, these results suggest that extracellular galectin-1 contributes to cancer progression and doxorubicin resistance in TNBC cells. These effects appear to be mediated by galectin-1-induced up-regulation of the integrin beta 1/FAK/c-Src/ERK/STAT3/survivin pathway. Our results imply that extracellular galectin-1 has potential as a therapeutic target for triple-negative breast cancer. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | IMPACT JOURNALS LLC | - |
dc.title | Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Shin, Incheol | - |
dc.identifier.doi | 10.18632/oncotarget.16208 | - |
dc.identifier.scopusid | 2-s2.0-85039700395 | - |
dc.identifier.wosid | 000403230000032 | - |
dc.identifier.bibliographicCitation | ONCOTARGET, v.8, no.22, pp.35804 - 35823 | - |
dc.relation.isPartOf | ONCOTARGET | - |
dc.citation.title | ONCOTARGET | - |
dc.citation.volume | 8 | - |
dc.citation.number | 22 | - |
dc.citation.startPage | 35804 | - |
dc.citation.endPage | 35823 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.subject.keywordPlus | GROWTH-FACTOR RECEPTOR | - |
dc.subject.keywordPlus | SERINE PHOSPHORYLATION | - |
dc.subject.keywordPlus | TUMOR PROGRESSION | - |
dc.subject.keywordPlus | ADHESION KINASE | - |
dc.subject.keywordPlus | GENE-EXPRESSION | - |
dc.subject.keywordPlus | UP-REGULATION | - |
dc.subject.keywordPlus | STAT3 | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | INVASION | - |
dc.subject.keywordAuthor | galectin-1 | - |
dc.subject.keywordAuthor | integrin beta 1 | - |
dc.subject.keywordAuthor | STAT3 | - |
dc.subject.keywordAuthor | survivin | - |
dc.subject.keywordAuthor | drug resistance | - |
dc.identifier.url | https://www.oncotarget.com/article/16208/text/ | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.